7 Results for "

radioimmunoconjugate

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "radioimmunoconjugate" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P99732
CAS No.: 195189-17-4
Synonyms: CC-49

Target:  

Mucin

Research Areas:  

Cancer

Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research .
loading...
    loading...
Cat. No.: HY-P99239
CAS No.: 2260767-49-3
Synonyms: HUJ-591; TLX591

Research Areas:  

Cancer

Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( 177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .
loading...
    loading...
Cat. No.: HY-156038
CAS No.: 1020407-41-3
Purity:  99.75%
(S)-p-SCN-Bn-DOTA is a bifunctional chelator (BFC), a macrocyclic DOTA derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
loading...
    loading...
Cat. No.: HY-P9992
CAS No.: 2414550-93-7
Synonyms: BAY-2315497; PSMA-TTC

Target:  

PSMA Apoptosis

Research Areas:  

Cancer

Peligifatamab is a PSMA-targeted α-radioimmunoconjugate with an EC50 of 1.2 nM against human targets. Peligifatamab induces DNA damage, DNA double-strand breaks, cell cycle arrest and apoptosis (Apoptosis) in PSMA-positive prostate cancer cells. Peligifatamab reduces cell viability in a manner dependent on cellular PSMA expression levels. Peligifatamab inhibits tumor growth and tumor-induced abnormal bone growth in prostate cancer bone metastasis models. Peligifatamab exhibits antitumor efficacy in subcutaneous prostate cancer models and xenograft models. Peligifatamab can be used for the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-P99581
CAS No.: 1612758-88-9
Synonyms: OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01

Research Areas:  

Cancer

Tabituximab barzuxetan (exclude Y90) (OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01) is a immunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101). Tabituximab barzuxetan exhibits anti-tumor activity. Tabituximab barzuxetan can be used for the research of synovial sarcoma .
loading...
    loading...
Cat. No.: HY-156038B
Target:  

Drug Derivative

Research Areas:  

Cancer

(S)-p-SCN-Bn-DOTA TFA is a bifunctional chelator (BFC), a macrocyclic DOTA (HY-W053583) derivative for tumor pretargeting. (S)-p-SCN-Bn-DOTA TFA can be used for the conjugation of peptides and radionuclides, such as as a linker for In-111 labeled radioimmunoconjugates (RICs) for single photon emission tomography (SPECT) and in vitro biodistribution studies .
loading...
    loading...
Cat. No.: HY-W1129940
CAS No.: 2417821-30-6
Research Areas:  

Cancer

p-SCN-Macropa is a bifunctional macrocyclic chelator featuring macrocyclic polyamine skeletons and thiocyanate (-SCN) reactive moieties. p-SCN-Macropa can conjugate with monoclonal antibodies including Nimotuzumab (HY-P9968), Rituximab (HY-P9913) and Trastuzumab (HY-P9907)-PEG6-DM1 for 225Ac radiolabeling to construct radioimmunoconjugates. p-SCN-Macropa is applicable for the research of colorectal cancer, HER2-positive breast cancer, TROP-2-positive cancers, and PSMA-positive cancers .
loading...
    loading...